Hepatitis C prevalence in the psychiatric setting: cost-effectiveness of scaling-up screening and direct-acting antiviral therapy
Published inJHEP Reports : Innovation in Hepatology, vol. 3, no. 3, 100279
Publication date2021
Abstract
Keywords
- Cost-effectiveness model
- DAA, direct-acting antiviral
- Direct-acting antiviral agents
- Hepatitis C infection
- ICER, Incremental cost-effectiveness ratio
- NMB, net monetary benefit
- PMI, patients with mental illnesses
- PSA, probabilistic sensitivity analysis
- Psychiatric disorder
- QALY, quality-adjusted life-year
- Screening strategy
- WTP, willingness-to-pay
Affiliation entities
- Faculté de médecine / Section de médecine fondamentale / Département de pathologie et immunologie
- Faculté de médecine / Section de médecine clinique / Département de médecine
- Faculté de médecine / Section de médecine clinique / Département de psychiatrie
- Faculté de médecine / Section de médecine clinique / Département d'anesthésiologie, pharmacologie, soins intensifs et urgences
Citation (ISO format)
GIRARDIN, François et al. Hepatitis C prevalence in the psychiatric setting: cost-effectiveness of scaling-up screening and direct-acting antiviral therapy. In: JHEP Reports : Innovation in Hepatology, 2021, vol. 3, n° 3, p. 100279. doi: 10.1016/j.jhepr.2021.100279
Identifiers
- PID : unige:151338
- DOI : 10.1016/j.jhepr.2021.100279
- PMID : 34522875
Additional URL for this publicationhttps://linkinghub.elsevier.com/retrieve/pii/S2589555921000550
Journal ISSN2589-5559